Seagen Inc. (SGEN) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Bothell, WA, United States. वर्तमान CEO हैं David R. Epstein.
SGEN के पास है IPO तिथि 2001-03-09, 3,256 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $43.15B.
Seagen Inc. is a biotechnology company headquartered in Bothell, Washington, specializing in the development and commercialization of cancer therapies. The company's commercial portfolio includes ADCETRIS for Hodgkin lymphoma and CD30-positive T-cell lymphomas, PADCEV for advanced urothelial cancer, and TUKYSA for HER2-positive breast cancer, alongside several pipeline candidates such as TIVDAK for cervical cancer and multiple novel antibody-drug conjugates targeting various oncology indications. Seagen operates globally and maintains strategic collaboration agreements with leading pharmaceutical companies including Takeda, Merck, and Genmab. The company was founded in 1997 as Seattle Genetics and rebranded as Seagen Inc. in 2020.
